Pentagalloyl glucose reverses chemoresistance in triple-negative breast cancer via EMT inhibition and miRNA modulation.

PGG reverses DOX resistance in TNBC cells through multiple mechanisms involving EMT inhibition, MDR suppression, and restoration of miR-200c-3p expression, suggesting that PGG holds promise as an adjuvant therapeutic agent for managing multidrug-resistant TNBC.